Certara, Inc. (NASDAQ:CERT) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Certara, Inc. (NASDAQ:CERT) by 29.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,721 shares of the company’s stock after acquiring an additional 9,330 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Certara were worth $403,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Janney Montgomery Scott LLC acquired a new position in shares of Certara during the first quarter worth about $120,000. First Trust Advisors LP acquired a new position in shares of Certara during the fourth quarter worth about $140,000. Illinois Municipal Retirement Fund grew its position in shares of Certara by 3.9% during the first quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company’s stock worth $591,000 after buying an additional 2,268 shares in the last quarter. Northern Trust Corp grew its position in shares of Certara by 14.0% during the fourth quarter. Northern Trust Corp now owns 877,010 shares of the company’s stock worth $9,340,000 after buying an additional 108,038 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Certara by 2.4% during the first quarter. Principal Financial Group Inc. now owns 543,958 shares of the company’s stock worth $5,385,000 after buying an additional 12,513 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Price Performance

CERT stock opened at $11.26 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.78 and a current ratio of 2.78. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $15.69. The firm has a market cap of $1.83 billion, a P/E ratio of 225.25 and a beta of 1.42. The stock has a 50-day simple moving average of $10.94 and a 200-day simple moving average of $11.78.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $104.57 million for the quarter, compared to analyst estimates of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. Certara’s revenue for the quarter was up 12.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.07 EPS. On average, equities analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CERT shares. Morgan Stanley started coverage on Certara in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 target price for the company. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. UBS Group decreased their target price on Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research note on Thursday. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. Finally, KeyCorp decreased their target price on Certara from $18.00 to $15.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Certara has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.